The GLP-1 Price War: Who's Winning and Who's Losing in 2026

The GLP-1 Price War Has Arrived

If you tried to get a GLP-1 medication two years ago, you were looking at $1,000 or more per month without insurance. The landscape in 2026 looks nothing like that. A full-blown price war has erupted among pharmaceutical companies, telehealth platforms, and compounding pharmacies, and patients are the clear winners. Monthly costs have dropped by as much as 85% compared to 2024 list prices, and the downward pressure shows no signs of letting up.

The catalyst was simple: competition. With more drugs on the market, more delivery channels, and Medicare coverage on the horizon, every player in the GLP-1 space is fighting for market share. Here is a breakdown of where prices stand right now and what it means for anyone considering treatment.

Foundayo Launches at $149 and Changes Everything

When Eli Lilly launched Foundayo (orforglipron) on April 1, 2026, they did not just introduce a new drug. They reset the entire pricing conversation. At $149 per month self-pay, Foundayo is the cheapest brand-name GLP-1 medication ever brought to market. For context, Wegovy's list price was over $1,300 per month when it launched in 2021.

Lilly's strategy is aggressive and deliberate. By pricing Foundayo below the threshold where most patients would even bother fighting with insurance companies, they are bypassing the traditional pharmacy benefit manager gatekeeping that slowed adoption of earlier GLP-1 drugs. The Foundayo launch guide covers the full details on how to get started, but the key takeaway is that affordability is no longer a barrier for most working Americans.

Foundayo also has a practical advantage beyond price: it is a daily pill that requires no fasting window and no injections. The combination of low cost and high convenience has driven enormous early demand.

Wegovy Subscription Programs: $249 Through Telehealth

Novo Nordisk has not sat idle while Lilly undercuts them. Through partnerships with major telehealth platforms like Hims and Ro, branded Wegovy is now available as part of subscription programs that bundle the medication, consultations, and ongoing monitoring for approximately $249 per month. That is a far cry from the $1,300 list price, though still notably more expensive than Foundayo.

The subscription model has its advantages. Patients get a known, proven medication with years of clinical data and real-world outcomes behind it. Semaglutide has demonstrated average weight loss of 15% or more in clinical trials, and many providers consider it the gold standard for GLP-1 therapy. For patients who want the most proven option and can absorb the higher monthly cost, Wegovy subscriptions through telehealth represent a solid middle ground.

However, the $100 per month premium over Foundayo is hard to justify for many patients, especially those paying entirely out of pocket. A recent GLP-1 price war analysis found that the pricing gap is pushing significant patient volume toward Foundayo and compounded alternatives.

Compounded Semaglutide: Still the Cheapest Option

Despite the arrival of affordable brand-name options, compounded semaglutide remains the lowest-cost entry point for GLP-1 therapy. Prices range from $99 to $150 per month through telehealth providers that work with 503A and 503B compounding pharmacies. Some programs offer even lower introductory rates.

The compounding market has matured considerably since its early days. Providers now offer standardized dosing protocols, regular follow-up consultations, and quality-tested products. The FDA's ongoing regulatory posture toward compounded GLP-1 medications remains a topic of discussion, but as of April 2026, compounded semaglutide continues to be legally available through properly licensed pharmacies when the branded versions face shortage designations.

The trade-off is straightforward: compounded semaglutide costs less but lacks the brand-name guarantee and may face future regulatory uncertainty. For budget-conscious patients, it remains a viable option worth discussing with a healthcare provider.

How to Compare Programs

With so many options available, comparing GLP-1 programs has become genuinely complicated. Prices vary not just by medication but by provider, subscription tier, included services, and geographic availability. Some programs bundle lab work and consultations while others charge separately. Some require long-term commitments while others are month-to-month.

Independent review sites have become essential tools for navigating this landscape. You can compare all 32 GLP-1 programs side by side, including pricing, provider ratings, medication options, and what is included in each subscription. Taking thirty minutes to research before committing can easily save hundreds of dollars per month.

Key factors to evaluate include: the specific medication offered, monthly total cost including consultations, cancellation policies, provider credentials, and patient reviews. Do not assume the cheapest option is always the best value, and do not assume the most expensive option delivers proportionally better results.

Medicare Coverage Arrives July 2026

The biggest upcoming shift in GLP-1 affordability is not coming from the private market at all. Starting in July 2026, Medicare will begin covering GLP-1 medications for weight management at an estimated patient cost of just $50 per month. This change, included in recent legislative updates, will make GLP-1 therapy accessible to millions of older Americans who were previously priced out entirely.

The Medicare coverage is expected to further intensify the price war in the private market. If the federal government is offering GLP-1 access at $50 per month for seniors, commercial insurers and self-pay programs will face enormous pressure to bring their prices closer to that benchmark. Industry analysts predict that average monthly costs across all channels could fall below $100 by the end of 2026.

The Bottom Line

The GLP-1 price war of 2026 has transformed weight loss medication from a luxury accessible only to the wealthy or well-insured into a broadly affordable treatment option. Foundayo at $149, Wegovy subscriptions at $249, and compounded semaglutide from $99 give patients real choices at real price points. With Medicare coverage arriving in July, the trajectory is clear: prices are going down, access is going up, and the era of thousand-dollar monthly GLP-1 bills is over.